Evidence map›Paper›PMID 40244436›Full record

ReviewWorld journal of urology2025

Renal fibrosis progression following partial unilateral ureteral obstruction: mechanisms and therapeutic insights.

Yomna Khater, Nashwa Barakat, Ahmed Shokeir, Alaa Samy, Gamal Karrouf

Abstract readReview
In one paragraph

Review in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. KMT5a-Mediated IRF3 Stabilization Enhances Macrophage Chemotaxis and Renal Fibrosis Progression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yomna KhaterMedical Experimental Research Centre, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
Nashwa BarakatUrology and Nephrology Center, Mansoura University, Mansoura, 35516, Egypt.
Ahmed ShokeirUrology and Nephrology Center, Mansoura University, Mansoura, 35516, Egypt.
Alaa SamyDepartment of Surgery, Anesthesiology, and Radiology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, 35516, Egypt.
Gamal KarroufDepartment of Surgery, Anesthesiology, and Radiology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, 35516, Egypt. gamalkarrouf@mans.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ureteral obstruction, a common clinical condition, is associated with various renal disorders affecting all age groups and can lead to permanent renal damage. In Partial unilateral ureteral obstruction (PUUO), increased ureteral pressure, and decreased glomerular filtration rate (GFR) in the affected kidney cause cellular and molecular abnormalities, which ultimately lead to renal fibrosis if untreated. While removing the obstruction (RUUO) is essential to prevent long-term damage, additional therapeutic approaches may be necessary to fully restore kidney function. The PUUO model is used to induce renal fibrosis, primarily characterized by tubular injury resulting from obstructed urine flow. PUUO in rodents can simulate human chronic obstructive nephropathy at an accelerated rate. Although alleviating the obstruction can reduce immediate symptoms, it is often insufficient to reverse established fibrosis, emphasizing the need for adjunctive therapies. The renal response to RUUO depends on factors like the obstruction's duration and severity, as well as the contralateral kidney's functional state.

Indexed as

KidneyKidney DiseasesUreteral ObstructionAnimalsDisease ProgressionFibrosisHumansFibrosisPartial unilateral ureteral obstructionPUUOTreatment

Identifiers

PMID40244436
PMCPMC12006208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.